TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS

Cardiovascular Research

Volumn 56, Issue 1, 2002, Pages 126-134

  Zeuke, Stefanie ^a,b   Ulmer, Artur J ^b   Kusumoto, Shoichi ^c   Katus, Hugo A ^a   Heine, Holger ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Cytokines; Endothelial factors; Endotoxins; Heart failure; Infection inflammation

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CERIVASTATIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CYTOKINE RELEASE; DISEASE COURSE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; INFLAMMATION; INFLAMMATORY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL ADHESION MOLECULES; CELLS, CULTURED; CHEMOKINE CCL2; CORONARY VESSELS; CYTOKINES; DROSOPHILA PROTEINS; E-SELECTIN; ENDOTHELIUM, VASCULAR; GLYCOLIPIDS; HEART FAILURE, CONGESTIVE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1; INTERLEUKIN-6; INTERLEUKIN-8; LIPID A; LIPOPOLYSACCHARIDES; MEMBRANE GLYCOPROTEINS; PYRIDINES; RECEPTORS, CELL SURFACE; RNA, MESSENGER; STIMULATION, CHEMICAL; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0036775020     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(02)00512-6     Document Type: Article

References (52)

1. Torre-Amione G., Kapadia S., Benedict C., et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol. 27:1996;1201-1206.
2. Lommi J., Pulkki K., Koskinen P., et al. Haemodynamic, neuroendocrine and metabolic correlates of circulating cytokine concentrations in congestive heart failure. Eur Heart J. 18:1997;1620-1625.
3. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 323:1990;236-241.
4. Ikeda U., Ito T., Shimada K. Interleukin-6 and acute coronary syndrome. Clin Cardiol. 24:2001;701-710.
5. Gabriel A.S., Ahnve S., Wretlind B., Martinsson A. IL-6 and IL-1 receptor antagonist in stable angina pectoris and relation of IL-6 to clinical findings in acute myocardial infarction. J Intern Med. 248:2000;61-66.
6. Kanda T., Inoue M., Kotajima N., et al. Circulating interleukin-6 and interleukin-6 receptors in patients with acute and recent myocardial infarction. Cardiology. 93:2000;191-196.
7. Lindmark E., Diderholm E., Wallentin L., Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. J Am Med Assoc. 286:2001;2107-2113.
8. Kelly R.A., Smith T.W. Cytokines and cardiac contractile function. Circulation. 95:1997;778-781.
9. Mann D.L., Young J.B. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest. 105:1994;897-904.
10. Niebauer J. Inflammatory mediators in heart failure. Int J Cardiol. 72:2000;209-213.
11. Rietschel E.T., Brade H. Bacterial endotoxins. Sci Am. 267:1992;53-61.
12. Weisensee D., Bereiter-Hahn J., Schoeppe W., Low-Friedrich I. Effects of cytokines on the contractility of cultured cardiac myocytes. Int J Immunopharmacol. 15:1993;581-587.
13. Hasper D., Hummel M., Kleber F.X., Reindl I., Volk H.D. Systemic inflammation in patients with heart failure. Eur Heart J. 19:1998;761-765.
14. Zhong W.W., Burke P.A., Hand A.T., et al. Regulation of cytokine mRNA expression in lipopolysaccharide-stimulated human macrophages. Arch Surg. 128:1993;158-163.
15. Comstock K.L., Krown K.A., Page M.T., et al. LPS-induced TNF-alpha release from and apoptosis in rat cardiomyocytes: obligatory role for CD14 in mediating the LPS response. J Mol Cell Cardiol. 30:1998;2761-2775.
16. Heim A., Zeuke S., Weiss S., Ruschewski W., Grumbach I.M. Transient induction of cytokine production in human myocardial fibroblasts by coxsackievirus B3. Circ Res. 86:2000;753-759.
17. Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.J., Mathison J.C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 249:1990;1431-1433.
18. Pugin J., Schurer-Maly C.C., Leturcq D., et al. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA. 90:1993;2744-2748.
19. Chow J.C., Young D.W., Golenbock D.T., Christ W.J., Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem. 274:1999;10689-10692.
20. Hoshino K., Takeuchi O., Kawai T., et al. Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 162:1999;3749-3752.
21. Poltorak A., He X., Smirnova I., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 282:1998;2085-2088.
22. Cowan D.B., Poutias D.N., del Nido P.J., McGowan F.X. Jr. CD14-independent activation of cardiomyocyte signal transduction by bacterial endotoxin. Am J Physiol Heart Circ Physiol. 279:2000;H619-H629.
23. Frantz S., Kobzik L., Kim Y.D., et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 104:1999;271-280.
24. Anker S.D., Egerer K.R., Volk H.D., et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol. 79:1997;1426-1430.
25. Niebauer J., Volk H.D., Kemp M., et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 353:1999;1838-1842.
26. Rauchhaus M., Doehner W., Francis D.P., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 102:2000;3060-3067.
27. Vanhoutte P.M. Vascular physiology: the end of the quest? Nature. 327:1987;459-460.
28. Morris T.E., Mattox P.A., Shipley G.D., Wagner C.R., Hosenpud J.D. The pattern of cytokine messenger RNA expression in human aortic endothelial cells is different from that of human umbilical vein endothelial cells. Transpl Immunol. 1:1993;137-142.
29. Galanos C., Luderitz O., Westphal O. Preparation and properties of a standardized lipopolysaccharide from salmonella abortus equi (Novo-Pyrexal). Zentraubl Bakteriol. 243:1979;226-244.
30. Imoto M., Yoshimura H., Yamamoto M., et al. Chemical synthesis of a biosynthetic precursor of lipid A with a phosphorylated tetraacyldisaccharide structure. Bull Chem Soc Jpn. 60:1987;2197-2204.
31. El Samalouti V.T., Schletter J., Chyla I., et al. Identification of the 80-kDa LPS-binding protein (LMP80) as decay-accelerating factor (DAF CD55). FEMS Immunol Med Microbiol. 23:1999;259-269.
32. Pfeiffer A., Bötcher A., Orso E., et al. Lipopolysaccharide and ceramide docking to CD14 provokes ligand specific receptor clustering in rafts. Eur J Immunol. 31:2001;3153-3164.
33. Lien E., Means T.K., Heine H., et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest. 105:2000;497-504.
34. Kothe H., Dalhoff K., Rupp J., et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation. 101:2000;1760-1763.
35. Rosenson R.S., Tangney C.C., Casey L.C. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 353:1999;983-984.
36. Renz H., Gong J.H., Schmidt A., Nain M., Gemsa D. Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. J Immunol. 141:1988;2388-2393.
37. Dzau V.J., Packer M., Lilly L.S., et al. Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med. 310:1984;347-352.
38. Simone J., Simoni G., Lox C.D., et al. Expression of adhesion molecules and von Willebrand factor in human coronary artery endothelial cells incubated with differently modified hemoglobin solutions. Artif Cells Blood Substit Immobil Biotechnol. 25:1997;211-225.
39. Jehle A.B., Li Y., Stechschulte A.C., Stechschulte D.J., Dileepan K.N. Endotoxin and mast cell granule proteases synergistically activate human coronary artery endothelial cells to generate interleukin-6 and interleukin-8. J Interferon Cytokine Res. 20:2000;361-368.
40. Li Y., Chi L., Stechschulte D.J., Dileepan K.N. Histamine-induced production of interleukin-6 and interleukin-8 by human coronary artery endothelial cells is enhanced by endotoxin and tumor necrosis factor-alpha. Microvasc Res. 61:2001;253-262.
41. Andreassen A.K., Nordoy I., Simonsen S., et al. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol. 81:1998;604-608.
42. Devaux B., Scholz D., Hirche A., Klovekorn W.P., Schaper J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J. 18:1997;470-479.
43. Jersmann H.P., Hii C.S., Hodge G.L., Ferrante A. Synthesis and surface expression of CD14 by human endothelial cells. Infect Immun. 69:2001;479-485.
44. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 21:2001;1712-1719.
45. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. J Am Med Assoc. 286:2001;64-70.
46. Jialal I., Stein D., Balis D., et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 103:2001;1933-1935.
47. Bickel C., Ruprecht H.J., Blankenberg S., et al. AtheroGene Group . Influence of HMG-CoA reductase inhibitors of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol. 82:2002;25-31.
48. Hayashidani S., Tsutsui H., Shiomi T., et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 105:2002;868-873.
49. Bauersachs J., Galuppo P., Fraccarollo D., Christ M., Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation. 104:2001;982-985.
50. Kjekshus J. Debate: Statins should be used in patients with heart failure. Curr Control Tirals Cardiovasc Med. 2:2001;268-270.
51. Mazzu A.L., Lettieri J.T., Kelly E., et al. Influence of renal function on the pharmacokinetics of cerivastatin in normocholesterolemic adults. Eur J Clin Pharmacol. 56:2000;69-74.
52. Takata M., Urakaze M., Temaru R., et al. Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/p42 mitogen activated protein kinase. Br J Pharmacol. 134:2001;753-762.